Efficacy and tolerability of 1000–4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy
- 8 November 2000
- journal article
- clinical trial
- Published by Elsevier in Epilepsy Research
- Vol. 42 (2-3) , 89-95
- https://doi.org/10.1016/s0920-1211(00)00158-3
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyPublished by Elsevier ,1998
- New antiepileptic drugs: a systematic review of their efficacy and tolerabilityBMJ, 1996
- The new generation of antiepileptic drugs: advantages and disadvantagesBritish Journal of Clinical Pharmacology, 1996
- The Clinical Pharmacokinetics of the Newer Antiepileptic DrugsClinical Pharmacokinetics, 1996
- Clinical pharmacokinetics of new antiepileptic drugsPharmacology & Therapeutics, 1995
- Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsyEpilepsy Research, 1995
- Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and ratsEuropean Journal of Pharmacology, 1993
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985
- Two antiepileptic drugs for intractable epilepsy with complex-partial seizures.Journal of Neurology, Neurosurgery & Psychiatry, 1982